Drug profile · INN
lebrikizumab
EBGLYSS
lebrikizumab (EBGLYSS) is a interleukin-13 inhibitor. Associated with S.A..
EMA: approved PMDA: approved Dermatologicals (D11) D11AH10
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — lebrikizumab
- Class
- Dermatologicals (D11)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
lebrikizumab (EBGLYSS) is a interleukin-13 inhibitor. Associated with S.A..
Key facts
INN lebrikizumab
Brand EBGLYSS
Mechanism Interleukin-13 inhibitor
Target Interleukin-13
Therapeutic class Dermatologicals (D11)
ATC code D11AH10
Originator S.A.
Mechanism of action
Interleukin-13 inhibitor
Primary target: Interleukin-13
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lebrikizumab?
lebrikizumab (EBGLYSS) is a interleukin-13 inhibitor. Associated with S.A..
What is the brand name for lebrikizumab?
EBGLYSS is a marketed brand name for lebrikizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.